MOMELOTINIB COMBINATION THERAPY
The present disclosure relates to methods of treating an inflammatory disease or disorder, the method comprising: administering to a subject in need thereof a therapeutically effective amount of momelotinib (MMB) or a pharmaceutically acceptable salt thereof; and administering to the subject one or more anti-inflammatory agents, and combinations for use in treating an inflammatory disease or disorder.
1 . A method of treating an inflammatory disease or disorder, the method comprising:
administering to a subject in need thereof a therapeutically effective amount of momelotinib (MMB) or a pharmaceutically acceptable salt thereof; and administering to the subject one or more anti-inflammatory agents.
2 . The method of claim 1 , wherein the one or more anti-inflammatory agents is an agent that modulates NF-κB activity.
3 . The method of claim 1 , wherein the one or more anti-inflammatory agents is a BET protein inhibitor; optionally wherein the BET protein inhibitor is a BRD4 inhibitor.
4 . The method of claim 3 , wherein the BET protein inhibitor is selected from GSK2820151, GSK525762, GS-5829, RO6870810 (IV), BAY1238097, CC-90010, BMS-986158, INCB054329, INCB057643, ODM-207, AZD5153, FT-1101, ABBV-744, ABBV-075, PLX51107, BI894999, OTX015/MK8628, ZEN003694, RVX-000222, CPI-0610, apabetalone and fedratinib.
5 . The method of claim 1 , wherein the one or more anti-inflammatory agents is an IKK protein inhibitor; optionally wherein the IKK inhibitor is an IKKα, IKKβ, and/or IKKε inhibitor.
6 . The method of claim 4 , wherein the IKK inhibitor is selected from B1605906, MLN120B, PHA-408, LY2409881, PS-1145, and BMS-345541.
7 . The method of claim 1 , wherein the one or more anti-inflammatory agents is an IRAK and/or TLR inhibitor; optionally wherein the IRAK and/or TLR inhibitor is an IRAK1 inhibitor or IRAK4 inhibitor.
8 . The method of claim 7 , wherein the IRAK and/or TLR inhibitor is selected from BAY1 834845, CA-4948, PF-06650833 and pacritinib.
9 . The method of claim 1 , wherein treating the inflammatory disease or disorder comprises at least ameliorating one or more symptoms of the disease or disorder; optionally wherein amelioration of the one or more symptoms is increased as compared to a monotherapy with momelotinib (MMB) or a monotherapy with the one or more anti-inflammatory agents alone.
10 . The method of claim 1 , wherein the administering results in reduction in NF-κB pathway activity and modulation of JAK-STAT and ACVR1/SMAD signaling in cells of the subject.
11 . The method of claim 1 , wherein the subject has a chronic inflammatory disease, an autoimmune disease or cancer.
12 . A method of treating cancer comprising:
administering to a subject in need thereof a therapeutically effective amount of momelotinib (MMB) or a pharmaceutically acceptable salt thereof; and administering to the subject one or more anti-inflammatory agents.
13 . The method of claim 12 , wherein the one or more anti-inflammatory agents is an agent that modulates NF-κB activity.
14 . The method of claim 12 , wherein the one or more anti-inflammatory agents is a BET protein inhibitor; optionally wherein the BET protein inhibitor is a BRD4 inhibitor.
15 . The method of claim 14 , wherein the BET protein inhibitor is selected from GSK2820151, GSK525762, GS-5829, RO6870810 (IV), BAY1238097, CC-90010, BMS-986158, INCB054329, INCB057643, ODM-207, AZD5153, FT-1101, ABBV-744, ABBV-075, PLX51107, BI894999, OTX015/MK8628, ZEN003694, RVX-000222, CPI-0610, apabetalone and fedratinib.
16 . The method of claim 12 , wherein the one or more anti-inflammatory agents is an IKK protein inhibitor; optionally wherein the IKK inhibitor is an IKKα, IKKβ, and/or IKKε inhibitor.
17 . The method of claim 16 , wherein the IKK inhibitor is selected from B1605906, MLN120B, PHA-408, LY2409881, PS-1145, and BMS-345541.
18 . The method of claim 12 , wherein the one or more anti-inflammatory agents is an IRAK and/or TLR inhibitor.
19 . The method of claim 18 , wherein the IRAK and/or TLR inhibitor is an IRAK1 inhibitor or IRAK4 inhibitor; optionally wherein the IRAK and/or TLR inhibitor is selected from BAY1 834845, CA-4948, PF-06650833 and pacritinib.
20 . The method of claim 12 , wherein treating cancer comprises at least ameliorating one or more symptoms; optionally wherein amelioration of the one or more symptoms is increased as compared to a monotherapy with momelotinib (MMB) or a monotherapy with the one or more anti-inflammatory agents alone.
21 . The method of claim 12 , wherein the subject has myelofibrosis; optionally wherein the anti-inflammatory agent is CPI-0610.
22 . The method of claim 12 , wherein the administering results in reduction in NF-κB pathway activity and modulation of JAK-STAT and ACVR1/SMAD signaling in cells of the subject.